Chapters

Transcript

Video

Based on the CAHtalyst pediatric trial, were you able to down-titrate glucocorticoid doses in phase 2, evaluating the potential of crinecerfont to achieve glucocorticoid sparing in persons with CAH?

Based on the CAHtalyst pediatric trial, were you able to down-titrate glucocorticoid doses in phase 2, evaluating the potential of crinecerfont to achieve glucocorticoid sparing in persons with CAH?


Created by

CMEducation Resources | iQ&A Congenital Adrenal Hyperplasia (CAH) Medical Intelligence Zone 

Presenter

Phyllis W. Speiser, MD

Phyllis W. Speiser, MD

Associate Professor, Institute of Molecular Medicine
Feinstein Institutes for Medical Research
Emerita Professor, Pediatrics Donald and Barbara Zucker School of Medicine
Hofstra/Northwell
New Hyde Park, NY